Method for treating elevated intraocular pressure, including glaucoma

• US 6,969,514 B2
• Filed: 02/05/2003
• Issued: 11/29/2005
• Est. Priority Date: 02/05/2003
• Status: Expired due to Fees

• Current Assignee: David B. Soll
• Original Assignee: David B. Soll
• Inventors: Soll, David B.
• Primary Examiner(s): Lilling, Herbert J.
• Application Number:
  US10/358,466
• Publication Number:
  US 20040151714A1
• Time in Patent Office: 1,028 Days
• Field of Search: 424/94.62, 424/94.61, 424/428, 424/450
• US Class Current: 424/94.62
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics

Abstract

Hyaluronic acid, a polymer found in the trabecular meshwork of the eye, has a polymeric structure that is broken down by the enzyme hyaluronidase. A method is provided for reducing elevated intraocular pressure in an eye of a patient, such as a patient suffering from glaucoma, by administering modified hyaluronidase to the surface of the eye as a drop, spray, ointment, sustained-release or non-sustained release unit, and allowing the hyaluronidase to remain within the anterior chamber of the eye. The hyaluronidase is modified to enhance penetration through the corneal barrier, and is administered in an amount effective to reduce an elevated intraocular pressure. The method thus reduces the elevated intraocular pressure in the eye of a glaucoma patient without undesirable side effects.

Claims

1. A method for reducing elevated intraocular pressure in an eye comprising topically administering to the eye of a patient modified hyaluronidase, wherein the hyaluronidase is structurally modified with a transporter and is administered in an amount effective to reduce the intraocular pressure to a normal level, wherein the modified hyaluronidase is absorbed through a cornea into an anterior chamber of the eye.

2. The method according to claim 1, wherein the elevated intraocular pressure is caused by glaucoma.

3. The method according to claim 1, wherein the effective amount of modified hyaluronidase administered to the eye is about 5 to 25 USP units per ml.

4. The method according to claim 1, further comprising leaving the hyaluronidase in the eye following administration.

5. The method according to claim 1, wherein the modified hyaluronidase is administered to the eye as a drop, a spray, or an ointment.

6. The method according to claim 1, wherein the modified hyaluronidase is administered to the eye by a sustained or non-sustained release unit placed in a conjunctival cul-de-sac of the eye.

7. The method according to claim 1, wherein the effective amount of modified hyaluronidase administered to the eye is sufficient to achieve a hyaluronidase concentration of about 2 to about 25 USP units per ml aqueous humor in the anterior chamber of the eye.

8. The method according to claim 1, wherein the modified hyaluronidase is part of a liposome preparation.

9. The method according to claim 1, wherein the modified hyaluronidase is in the form of a gelable drop.

10. The method according to claim 1, wherein the hyaluronidase is modified with a transporter of oligomers of arginine or arginine-like monomers linked to a hyaluronidase molecule.

11. The method according to claim 1, wherein the normal level of intraocular pressure is less than about 20 mm Hg gauge.

12. The method according to claim 11, wherein the normal level of intraocular pressure is about 10 to about 18 mm Hg gauge.

13. The method according to claim 1, wherein the modified hyaluronidase is administered to the eye repeatedly and wherein the intraocular pressure remains at a normal level.

14. A method for reducing elevated intraocular pressure in an eye comprising topically administering to the eve of a patient modified hyaluronidase, wherein the modified hyaluronidase is in a form of a cochleate and is administered in an amount effective to reduce the intraocular pressure to a normal level.